Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The research team will evaluate the effectiveness of an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention: Auto-pended bot liver ultrasound order | Participants in the intervention group will receive an auto-pended bot liver ultrasound order that will prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening. |
| |
| Control: Usual Care | Participants in the control group will not receive the auto-pended bot liver ultrasound order. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Auto-pended bot liver ultrasound order | Other | This alert prompt providers at the time of encounter to place appropriate imaging orders for hepatocellular carcinoma (HCC) screening in patients with cirrhosis. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants for whom the Physician Completed Ordering of the Pending Liver Ultrasound | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Completed Liver Ultrasound Imaging | Day 1 | |
| HCC Diagnosis Rate from Completed Liver Ultrasound Imaging | Day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients presenting with a cirrhosis diagnosis, and at the date of their appointment had been 6 months or more after their most recent imaging.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Saul Blecker | NYU Langone Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | United States |
This is a quality improvement (QI) project and individual participant data (IPD) will not be shared with other researchers.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| D005355 | Fibrosis |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |